RGEN
RGEN
NASDAQ · Life Sciences Tools & Services

Repligen Corp

$126.37
-0.20 (-0.16%)
As of Jun 23, 9:47 PM ET ·
Financial Highlights (FY 2026)
Revenue
736.26M
Net Income
48.76M
Gross Margin
52.6%
Profit Margin
6.6%
Rev Growth
-2.7%
D/E Ratio
0.26
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 52.6% 52.6% 33.3% 33.3%
Operating Margin 7.5% 6.7% 6.8% 6.5%
Profit Margin 6.6% 6.3% 7.1% 6.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 736.26M 756.69M 4.59B 4.00B
Gross Profit 387.64M 398.40M 1.53B 1.33B
Operating Income 55.00M 50.87M 311.12M 261.18M
Net Income 48.76M 45.10M 325.04M 256.90M
Gross Margin 52.6% 52.6% 33.3% 33.3%
Operating Margin 7.5% 6.7% 6.8% 6.5%
Profit Margin 6.6% 6.3% 7.1% 6.4%
Rev Growth -2.7% -2.7% +1.3% +8.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 762.23M 762.23M 1.77B 1.35B
Total Equity 2.96B 2.96B 3.56B 3.35B
D/E Ratio 0.26 0.26 0.50 0.40
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 133.55M 130.39M 499.02M 399.89M
Free Cash Flow 285.62M 226.18M